FDA Alphabet Soup: OMQ, OPQ, OPMA... Who’s Actually Reviewing My Inspection?

On this episode of The Regulatory Mix, we break down FDA’s updated Concept of Operations for Facility Evaluation and Inspection of Human Drugs and answer a deceptively simple question:

After the investigator leaves, who is actually reviewing my inspection?

The answer depends on the type of inspection and what FDA is evaluating.

The updated ConOps lays out how responsibilities are divided across Preapproval, Postapproval, Surveillance, and For-Cause inspections. OII generally leads the field inspection, while offices within CDER, including OPQ, OPMA, OQS, and OMQ, take on different roles in facility risk assessment, application decisions, inspection classification, and compliance follow-up.

For a preapproval inspection, OPMA may be heavily involved because the question is whether the facility can support approval of a pending application. During routine surveillance, OQS helps drive risk-based site selection and develops the quality intelligence used before the inspection, while OMQ becomes particularly important when findings move toward VAI or OAI classification and potential compliance action.

The document also shows how FDA is increasingly blending traditional inspections with Remote Regulatory Assessments, Section 704(a)(4) records requests, Remote Interactive Evaluations, and Mutual Recognition Agreement inspection reports. The inspection is only one piece of a much larger facility evaluation process.

That means your Form FDA 483 response may ultimately be evaluated alongside application commitments, prior inspection history, complaints, recalls, quality intelligence, remote records, and information from other regulatory authorities.

The takeaway: the investigator may conduct the inspection, but the regulatory decision can involve several different offices after the inspection is over. Understanding who owns that next decision helps explain why inspection responses need to address more than just the individual observations on the Form FDA 483.

Source: FDA – Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations https://www.fda.gov/media/107225/download?attachment

Disclosure: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice.

Sponsored by Tailwind Pharma, LLC, a pharmaceutical quality and regulatory consulting firm specializing in FDA inspections, CGMP compliance, sterile manufacturing, data integrity, investigations, and regulatory strategy. Learn more at tailwindconsult.com.